World Sleep Industry ENCYCLOPEDIA

Insomnia Patient Recruitment

6.5.2

Definition, purpose, and service boundaries

Insomnia participant recruitment is the end-to-end process of identifying, approaching, prescreening, formally screening, and enrolling people with the insomnia characteristics required by an ethically approved research question. The population may consist of people with chronic insomnia disorder, short-term symptoms, insomnia coexisting with another condition, a particular age or life stage, or a control group, depending on whether the study is observational or concerns a behavioral intervention, digital therapeutic, drug, device, or mechanism. Within WSIC 6.5.2, “Subject and Sample Management,” the focus is insomnia-specific eligibility, safety, and representation, not referral to routine care or a treatment recommendation.

An advertisement respondent, high scorer on a questionnaire, clinically diagnosed patient, protocol-eligible person, consented participant, and randomized participant are not the same denominator. A recruitment team may explain the study, obtain permission to contact, and prescreen from an approved script, but it cannot promise a diagnosis, eligibility, allocation, or benefit. Research eligibility also does not decide whether an individual needs treatment. Health concerns found in screening should follow a predefined referral path; research screening must not be marketed as a free comprehensive sleep evaluation.

The recruitment plan should define the population, geography, languages, channels, stage-specific criteria, data sources, contact attempts, privacy basis, compensation, screening examinations, referrals, expected pace, and stopping rules. Investigators, sponsors, recruitment vendors, clinical sites, remote staff, and advertising platforms need a responsibility matrix. Outreach and prescreening may be contracted out, but protocol eligibility, risk decisions, informed consent, final enrollment, and oversight of participant rights remain with the authorized research team.

Target population, recruitability, and representation

Before outreach, the research question should become necessary and verifiable eligibility criteria. Insomnia may involve difficulty initiating or maintaining sleep, waking too early, or dissatisfaction with sleep quality together with daytime distress or functional effect, in the presence of a reasonable opportunity and circumstances for sleep. Symptom frequency, duration, severity, age range, and any requirement for clinical diagnosis should follow the diagnostic framework and version named in the protocol. They should not shift during recruitment, and neither a statement of “poor sleep” nor a consumer-device score alone establishes eligibility.

Feasibility should distinguish potentially relevant records, people who may lawfully be contacted, positive prescreens, completed formal screens, eligible candidates, consented participants, enrolled participants, and randomized participants, with expected attrition and timing at every step. Counts in medical records, communities, employer lists, social media, or volunteer databases are not directly enrollable totals. Nighttime testing, travel, caregiving, shift work, digital access, language, cost, current treatment, and the overall research burden shape willingness, so site and channel plans need to fit how the intended population actually lives.

Each exclusion needs a safety or scientific rationale. Blanket exclusion of psychiatric, pain, cardiovascular, metabolic, or other sleep comorbidity can create a rare “pure insomnia” sample with poor generalizability. A condition may nevertheless warrant exclusion, stratification, or stability criteria when it makes the intervention unsafe, obscures the primary outcome, or requires priority care. Recruitment metrics should be reviewed by age, sex, socioeconomic circumstances, language, geography, and relevant comorbidity. Channels and support may be adjusted when representation is deficient, but eligibility must not be changed after viewing outcome direction to alter the result.

Staged screening and confirmation of insomnia phenotype

Screening is best organized in stages. Brief self-report and validated questionnaires can identify people needing further assessment, but a questionnaire threshold is a prescreening tool, not a diagnosis by itself. Follow-up should review nighttime symptoms, daytime consequences, circumstances, course, weekly pattern, opportunity for sleep, schedule, workday versus free-day differences, and the person's understanding of the problem and treatment. When the protocol requires a clinical diagnosis, a qualified professional should apply the designated criteria; a call center or automated algorithm should not make the final determination.

A sleep diary can capture bed entry, attempted sleep, estimated sleep onset, wake during the night, final awakening, rising, naps, medication, and perceived quality. Actigraphy can supplement multiday timing and activity information. Polysomnography is generally used for a specific differential question, outcome, or protocol requirement, not as a universal gate proving every case of insomnia. Disagreement between subjective experience and instrument estimate does not automatically demonstrate exaggeration or invalid data. Both should be retained for their planned uses, with checks of wear, algorithm, time zone, dates across midnight, and diary completeness.

The phenotype should match the intervention mechanism and outcome, such as sleep initiation, maintenance, early awakening, circadian phase, hyperarousal, daytime functioning, and comorbidity, rather than pooling every sleep complaint to accelerate accrual. A control group also needs a definition: no insomnia disorder, low symptoms, healthy controls, or disease controls are different populations and need assessment comparable to the cases. An unexamined lack of complaint is not proof of health. Screen-failure reasons should use nonstigmatizing, analyzable categories, while candidates are told the limited meaning of a research eligibility decision.

Differential assessment, comorbidity, and safety routing

Formal screening should consider insufficient sleep opportunity, circadian misalignment, shift work, obstructive sleep apnea, restless legs, periodic limb movements, parasomnias, narcolepsy, pain, nocturia, respiratory or cardiac symptoms, medicines, and substances as other explanations. Questionnaires identify risk but do not decide when a clinical examination, home sleep test, polysomnogram, or laboratory test is required; the protocol and qualified clinicians do. Insomnia can coexist with another sleep disorder, so another disorder neither automatically disproves insomnia nor may be ignored to preserve eligibility when it needs priority attention.

Mental and behavioral safety assessment should be proportionate to the study and address depression, anxiety, trauma, mania or hypomania, psychotic experiences, substance use or withdrawal, cognitive capacity, and risk of harm to self or others. A stable comorbidity should not trigger exclusion by label alone; current severity, stability, intervention interactions, consent capacity, and required support matter. Acute danger, severe decompensation, or hazardous sleepiness while driving or working should interrupt routine recruitment and activate local, timely clinical or emergency routing whose completion can be confirmed, rather than supplying a phone number and continuing the screen.

Some behavioral insomnia interventions alter time in bed and may temporarily increase sleepiness; drug studies may add sedation, falls, cognition, respiration, pregnancy, reproductive, misuse, or withdrawal risks. Screening should consider the specific intervention in the context of driving, heights, machinery, weapons, caregiving, seizures, bipolar disorder, older-adult falls, and the home environment. Safety criteria cannot simply be copied from another trial, and recruitment staff should not improvise clinical care. Complex judgments need escalation to authorized research clinicians with the basis recorded.

Current care, research burden, and informed consent

Screening should reconcile prescriptions, nonprescription sleep aids, supplements, alcohol and other substances, psychotherapy, digital sleep programs, positive airway pressure, and recent changes. If the protocol requires stable care, washout, or suspension, it should specify the scientific reason, responsible clinician, monitoring, and fallback. Candidates must not stop a medicine or device or change treatment on their own to qualify. When a change could cause rebound insomnia, withdrawal, mood worsening, or another risk, investigators and the appropriate treating team should assess it, with the genuine option to keep treatment unchanged and decline the study.

Consent should accurately describe nighttime visits, diaries, wearables, laboratory alterations to sleep, random allocation, placebo or wait conditions, adherence expectations, specimens and data, privacy, possible discomfort, alternatives, and withdrawal. A person with insomnia may review information while sleepy at night, fatigued by day, or anxious, so the process needs adequate time, plain language, questions, and an assessment of understanding. Participation does not guarantee better sleep. Placebo is not “nothing happening,” and run-in periods or behavioral requirements can themselves be burdensome.

Compensation should distinguish payment for time and inconvenience, reimbursement of travel or lodging, and payment for completed procedures and should receive applicable review. Credit for completed portions should accrue fairly rather than holding most payment until the end. Arrangements may address evening transport, next-day work, replacement caregiving, parking, remote devices, and connectivity. These measures reduce structural barriers; they should not induce someone in financial hardship to accept unwanted risk. Declining, screen failure, or withdrawal should not impair access to routine care.

Outreach channels, remote processes, and authenticity

Materials should accurately describe the study, major procedures, time burden, basic criteria, location or remote requirements, and contact method. They should not promise to “cure insomnia,” claim no risk, or guarantee benefit. Search advertising around insomnia, nighttime delivery, and anxiety-based messages may reach people while distressed or impulsive, making fear and artificial countdowns particularly inappropriate. Advertisements, landing pages, automated responses, call scripts, short videos, and shareable content form one version-controlled information environment; unapproved comment replies must not expand study claims.

Before using health records, portals, pharmacies, communities, workplaces, or social media to find candidates, the project should establish a lawful basis for each access and contact and use only what prescreening needs. Names, symptoms, mental-health risks, medicines, and contact details from people who never enroll remain sensitive and need retention, access, and deletion rules. Platform profiling may expose a person's apparent interest in insomnia or mental health without their awareness. The team should review tracking pixels, third-party analytics, and retargeting and offer routes that do not depend on one platform or a smartphone.

Remote processes should verify identity, current location, emergency contact, and local support as appropriate. Electronic consent, diaries, and device delivery need usability assessment in the intended population, with accommodations for hearing, vision, cognition, language, and digital skill. Bots, duplicate applications, impersonation, and fabricated symptoms for compensation can be addressed through layered reconciliation, consistency checks, and human review. A shared address, limited digital footprint, or language difference must not automatically be treated as fraud. Verification should match risk and avoid collecting more identity data than necessary.

Enrollment handoff, quality measures, and vendor governance

Eligibility confirmation should use a versioned checklist documenting each item of evidence, decision maker, date, exception, and medical escalation. Enrollment or randomization follows only after applicable consent and baseline requirements are complete. The recruitment team should accurately hand off contact preferences, accessibility needs, safety alerts, current care, pending tests, and promised arrangements to the site under the minimum-necessary principle. People who screen out should receive the predefined explanation and referral information without a diagnostic conclusion beyond the evidence collected.

Quality review should separately track impressions, inquiries, permission to contact, prescreens, formal screens, eligibility, consent, enrollment, and randomization, together with time at each stage, failure reasons, loss to contact, withdrawal, channel yield, duplicates or fraud, completed referrals, and demographic differences. The cheapest enrollment or highest click rate is not automatically the best channel; large volumes of misleading leads increase privacy and site burdens. Protocol amendments, channel changes, and criterion clarifications need assessment for effects on existing candidates, representation, and selection bias, with versions retained.

When recruitment is contracted, due diligence should examine script control, staff training, privacy and security, subcontracting, platform tracking, crisis escalation, complaints, audit records, and shutdown procedures. Agreements should prohibit selling or repurposing leads, unauthorized retargeting, enrollment-linked promises, and opaque algorithmic exclusion. At closeout, the parties should reconcile candidate records, consent and contact authority, screening status, unresolved risks, compensation, return of data, and deletion evidence. A vendor's list of names does not show that investigators fulfilled eligibility and participant-protection duties.